CLIMB BIO, INC. Stock-Based Compensation
CLIMB BIO, INC. (CLYM) reported Stock-Based Compensation of $3.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.48M, a 46.20% increase year-over-year.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.60M, a 20.62% decline year-over-year.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.04M, a 37.09% decline year-over-year.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.98M, a 36.07% increase year-over-year.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $8.05M, a 44.93% increase from fiscal 2024.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $5.56M, a 56.61% decline from fiscal 2023.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $12.81M, a 83.18% increase from fiscal 2022.
- CLIMB BIO, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $6.99M, a 87.08% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.09M 10-Q · filed 2026-08-06 | $4.13M derived: sum of 3 quarters · filed 2026-08-06 | $8.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.60M 10-Q · filed 2026-05-07 | $2.65M derived: sum of 2 quarters · filed 2026-05-07 | $6.62M derived: sum of 3 quarters · filed 2026-05-07 | $7.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.02M derived: sum of 2 quarters · filed 2026-03-05 | $6.03M derived: sum of 3 quarters · filed 2026-08-06 | $8.05M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.99M derived: sum of 2 quarters · filed 2026-08-06 | $7.01M 10-Q · filed 2025-11-06 | $8.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.04M 10-Q · filed 2026-08-06 | $4.69M derived: sum of 3 quarters · filed 2026-08-06 | $7.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.02M 10-Q · filed 2026-05-07 | $3.68M derived: sum of 2 quarters · filed 2026-05-07 | $6.60M derived: sum of 3 quarters · filed 2026-05-07 | $7.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.58M derived: sum of 2 quarters · filed 2026-03-05 | $5.09M derived: sum of 3 quarters · filed 2026-03-05 | $5.56M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.43M derived: sum of 2 quarters · filed 2025-11-06 | $3.90M 10-Q · filed 2025-11-06 | $5.10M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $512.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $977.00K 10-Q · filed 2025-08-12 | $2.18M derived: sum of 3 quarters · filed 2025-08-12 | $2.83M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $465.00K 10-Q · filed 2025-05-14 | $1.67M derived: sum of 2 quarters · filed 2025-05-14 | $2.32M derived: sum of 3 quarters · filed 2025-05-14 | $3.10M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $1.86M derived: sum of 2 quarters · filed 2025-03-25 | $2.63M derived: sum of 3 quarters · filed 2025-03-25 | $12.81M 10-K · filed 2025-03-25 |
| 2023-09-30 | $656.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.43M derived: sum of 2 quarters · filed 2024-11-12 | $11.60M 10-Q · filed 2024-11-12 | $13.50M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $777.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $10.95M 10-Q · filed 2024-08-14 | $12.84M derived: sum of 3 quarters · filed 2024-08-14 | $14.63M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $10.17M 10-Q · filed 2024-05-15 | $12.07M derived: sum of 2 quarters · filed 2024-05-15 | $13.85M derived: sum of 3 quarters · filed 2024-05-15 | $15.62M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.68M derived: sum of 2 quarters · filed 2024-03-28 | $5.45M derived: sum of 3 quarters · filed 2024-03-28 | $6.99M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.56M derived: sum of 2 quarters · filed 2023-11-14 | $5.10M 10-Q · filed 2023-11-14 | $6.25M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.31M 10-Q · filed 2023-08-10 | $4.47M derived: sum of 3 quarters · filed 2023-08-10 | $5.70M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.54M 10-Q · filed 2023-05-11 | $2.69M derived: sum of 2 quarters · filed 2023-05-11 | $3.93M derived: sum of 3 quarters · filed 2023-05-11 | $4.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.39M derived: sum of 2 quarters · filed 2023-03-06 | $3.44M derived: sum of 3 quarters · filed 2023-03-06 | $3.74M 10-K · filed 2023-03-06 |
| 2021-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.29M derived: sum of 2 quarters · filed 2022-11-14 | $2.58M 10-Q · filed 2022-11-14 | $3.06M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.35M 10-Q · filed 2022-08-15 | $1.82M derived: sum of 3 quarters · filed 2022-08-15 | $1.87M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $297.00K 10-Q · filed 2022-05-16 | $770.00K derived: sum of 2 quarters · filed 2022-05-16 | $819.00K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $522.00K derived: sum of 2 quarters · filed 2022-03-07 | $707.00K 10-K · filed 2022-03-07 | |
| 2020-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $234.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $185.00K 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |